Cargando…

Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways

Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Halani, Sameer H., Yousefi, Safoora, Velazquez Vega, Jose, Rossi, Michael R., Zhao, Zheng, Amrollahi, Fatemeh, Holder, Chad A., Baxter-Stoltzfus, Amelia, Eschbacher, Jennifer, Griffith, Brent, Olson, Jeffrey J., Jiang, Tao, Yates, Joseph R., Eberhart, Charles G., Poisson, Laila M., Cooper, Lee A. D., Brat, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219505/
https://www.ncbi.nlm.nih.gov/pubmed/30417117
http://dx.doi.org/10.1038/s41698-018-0067-9
_version_ 1783368665745326080
author Halani, Sameer H.
Yousefi, Safoora
Velazquez Vega, Jose
Rossi, Michael R.
Zhao, Zheng
Amrollahi, Fatemeh
Holder, Chad A.
Baxter-Stoltzfus, Amelia
Eschbacher, Jennifer
Griffith, Brent
Olson, Jeffrey J.
Jiang, Tao
Yates, Joseph R.
Eberhart, Charles G.
Poisson, Laila M.
Cooper, Lee A. D.
Brat, Daniel J.
author_facet Halani, Sameer H.
Yousefi, Safoora
Velazquez Vega, Jose
Rossi, Michael R.
Zhao, Zheng
Amrollahi, Fatemeh
Holder, Chad A.
Baxter-Stoltzfus, Amelia
Eschbacher, Jennifer
Griffith, Brent
Olson, Jeffrey J.
Jiang, Tao
Yates, Joseph R.
Eberhart, Charles G.
Poisson, Laila M.
Cooper, Lee A. D.
Brat, Daniel J.
author_sort Halani, Sameer H.
collection PubMed
description Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers for stratifying risk. We utilized machine-learning approaches with genomic data from The Cancer Genome Atlas to objectively identify molecular factors associated with clinical outcomes of oligodendroglioma and extended these findings to study signaling pathways implicated in oncogenesis and clinical endpoints associated with glioma progression. Our multi-faceted computational approach uncovered key genetic alterations associated with disease progression and shorter survival in oligodendroglioma and specifically identified Notch pathway inactivation and PI3K pathway activation as the most strongly associated with MRI and pathology findings of advanced disease and poor clinical outcome. Our findings that Notch pathway inactivation and PI3K pathway activation are associated with advanced disease and survival risk will pave the way for clinically relevant markers of disease progression and therapeutic targets to improve clinical outcomes. Furthermore, our approach demonstrates the strength of machine learning and computational methods for identifying genetic events critical to disease progression in the era of big data and precision medicine.
format Online
Article
Text
id pubmed-6219505
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62195052018-11-09 Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways Halani, Sameer H. Yousefi, Safoora Velazquez Vega, Jose Rossi, Michael R. Zhao, Zheng Amrollahi, Fatemeh Holder, Chad A. Baxter-Stoltzfus, Amelia Eschbacher, Jennifer Griffith, Brent Olson, Jeffrey J. Jiang, Tao Yates, Joseph R. Eberhart, Charles G. Poisson, Laila M. Cooper, Lee A. D. Brat, Daniel J. NPJ Precis Oncol Article Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers for stratifying risk. We utilized machine-learning approaches with genomic data from The Cancer Genome Atlas to objectively identify molecular factors associated with clinical outcomes of oligodendroglioma and extended these findings to study signaling pathways implicated in oncogenesis and clinical endpoints associated with glioma progression. Our multi-faceted computational approach uncovered key genetic alterations associated with disease progression and shorter survival in oligodendroglioma and specifically identified Notch pathway inactivation and PI3K pathway activation as the most strongly associated with MRI and pathology findings of advanced disease and poor clinical outcome. Our findings that Notch pathway inactivation and PI3K pathway activation are associated with advanced disease and survival risk will pave the way for clinically relevant markers of disease progression and therapeutic targets to improve clinical outcomes. Furthermore, our approach demonstrates the strength of machine learning and computational methods for identifying genetic events critical to disease progression in the era of big data and precision medicine. Nature Publishing Group UK 2018-11-06 /pmc/articles/PMC6219505/ /pubmed/30417117 http://dx.doi.org/10.1038/s41698-018-0067-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Halani, Sameer H.
Yousefi, Safoora
Velazquez Vega, Jose
Rossi, Michael R.
Zhao, Zheng
Amrollahi, Fatemeh
Holder, Chad A.
Baxter-Stoltzfus, Amelia
Eschbacher, Jennifer
Griffith, Brent
Olson, Jeffrey J.
Jiang, Tao
Yates, Joseph R.
Eberhart, Charles G.
Poisson, Laila M.
Cooper, Lee A. D.
Brat, Daniel J.
Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
title Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
title_full Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
title_fullStr Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
title_full_unstemmed Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
title_short Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
title_sort multi-faceted computational assessment of risk and progression in oligodendroglioma implicates notch and pi3k pathways
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219505/
https://www.ncbi.nlm.nih.gov/pubmed/30417117
http://dx.doi.org/10.1038/s41698-018-0067-9
work_keys_str_mv AT halanisameerh multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT yousefisafoora multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT velazquezvegajose multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT rossimichaelr multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT zhaozheng multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT amrollahifatemeh multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT holderchada multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT baxterstoltzfusamelia multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT eschbacherjennifer multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT griffithbrent multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT olsonjeffreyj multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT jiangtao multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT yatesjosephr multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT eberhartcharlesg multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT poissonlailam multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT cooperleead multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways
AT bratdanielj multifacetedcomputationalassessmentofriskandprogressioninoligodendrogliomaimplicatesnotchandpi3kpathways